throbber
ELSEVIER
`
`Regulatory Peptides 79 (1999) 153-158
`
`REGULATORY
`
`PEPTIDES
`
`CGRP 27-37 analogues with high affinity to the CGRP1 receptor show
`antagonistic properties in a rat blood flow assay
`
`Beate Rista, J. Silvain Lacroixb, Michael Entzeroth\ Henry N. Doodsc,
`Annette G. Beck-Sickingera·*
`
`'Department of Pharmacy, ETH Zurich, Willterthurer Str. 190, CH 8057 Zurich, Switzerland
`•Department of Otorhinolaryngology, Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland
`cDepartment of Biochemical Research, Dr. Karl Thomae GmbH, Biberach, Germany
`
`Received 5 May 1998; received in revised form 6 November 1998; a_ccepted 6 November 1998
`
`Abstract
`
`CGRP Y0 -28-37 is known as a selective CGRP1 receptor antagonist. We succeeded in optimising the CGRP1 receptor affinity of this
`fragment by multiple amino acid replacement. The analogues [P34
`, F 3 5)CGRP 27-37 and [D 31
`, P 34
`, F 35)CGRP 27-37 exhibit a 100-fold
`increased affinity compared to the unmodified segment. Receptor binding studies were performed with human neuroblastoma cells
`SK-N-MC, which selectively express the hCGRP, receptor. Blood flow, which is increased by exogenous CGRP, was measured in the
`right femoral artery. Preincubation of the rats with [P34
`, F 35]CGRP 27-37 and [D 31
`, P 3 4
`, F 35]CGRP 27-37 led to a significant decrease in
`CGRP induced increase in vascular conductance indicating the antagonistic properties of these compounds. Interestingly, an exchange of
`the amino acid Asn 31 to Asp 31 in [P3 4
`, F 35]CGRP 27- 37 shortened the period of the antagonistic effect significantly, suggestive of a
`different rate of metabolism for the two ligands. Secondary structure investigations obtained by circular dichroism measurements revealed
`that an increase in ordered structure correlates with high binding affinity. © 1999 Elsevier Science B:V. All rights reserved.
`
`Keywords: CGRP, receptor antagonist; Neuroblastoma cells; Vascular conductance; Circular dichroism; Synthetic peptides; Peptide
`mime tics
`
`1. Introduction
`
`Calcitonin gene-related peptide (CGRP) is a 37-amino
`acid peptide generated by alternative tissue-specific splic(cid:173)
`ing of the primary transcript of the calcitonin [1,2]. In
`contrast to calcitonin which is predominantly expressed in
`the C-cells of the thyroid, two forms (a. and (3) of CGRP
`are produced in a variety of human tissues which are
`mostly of neuronal origin [3,4]. In fact, CGRP is co(cid:173)
`localised with substance P in sensory nerves, with acetyl(cid:173)
`choline in motorneurones, and with various other transmit(cid:173)
`ters in the brain (for review see Ref. [5]).
`A variety of biological effects have been reported for
`
`*corresponding author. Tel.: + 41-1-635-6063; fax: + 41-1-635-6884;
`e-mail: beck-sickinger@pharma.ethz.ch
`
`CGRP such as peripheral blood vessel dilatation, an
`increase in heart rate, regulation of calcium metabolism
`and insulin secretion, reduction of gastric acid secretion,
`increase in body temperature, and decrease in food uptake
`[5]. These effects have been suggested to be mediated by
`at least two receptor subtypes (CGRP1 and CGRP2 ) [6,7]
`which are both G-protein coupled. The hCGRP1 receptor
`has been cloned recently [8].
`Structure-activity studies of reduced size CGRP ana(cid:173)
`logues showed that the C- and N-terrninal region of the
`hormone interact independently with their receptors. Since
`we were interested in antagonistic ligands at the hCGRP1
`receptor, we focused on the optimisation of the structurally
`poorly defined C-termina'l part of the hormone. The
`segment CGRP Y0-28- 37 which is reported as a selective
`CGRP1 receptor antagonist [9,10], however with low
`
`0167-0115/99/$- see front matter © 1999 Elsevier Science B:V. All rights reserved.
`PII : SOI67-0115(98)00159-l
`
`EX2008
`Eli Lilly & Co. v. Teva Pharms. Int'l GMBH
`IPR2018-01423
`
`1
`
`

`

`154
`
`B. Rist et al. I Regulatory Peptides 79 (1999) 153-158
`
`affinity. No activity has been found up to the micromolar
`concentration [11] which is in agreement with our results.
`In order to improve binding affinity, multiple amino acid
`replacement within this segment has been performed [12]
`and resulted in a series of high affinity ligands, including
`, F 35]CGRP 27-37 and [D 31
`, P 34
`, F 35]CGRP 27-37.
`[P 34
`Within the present study we could confirm the suggested
`antagonistic properties of C-terminal analogues of CGRP
`Y0-28-37 using a rat in vivo assay. Furthermore, we were
`able to identify a portion of the peptide sequence which
`appears to be sensitive to proteolytic cleavage but does not
`affect receptor binding affinity.
`Circular dichroism studies have been performed in order
`to elucidate the difference in secondary structure between
`peptidic ligands exhibiting poor and high receptor binding
`affinities, respectively.
`
`2. Methods
`
`2.1. Peptide synthesis
`
`The linear peptides were synthesised by automated
`multiple solid phase peptide synthesis using a robot system
`(Syro, MultiSynTech, Bochum). In order to obtain a
`peptide amide, 4-(2' ,4' -dimethoxyphenyl-Fmoc-amino(cid:173)
`methyl)-phenoxy resin was used. The polymer matrix was
`polystyrene-! %-divinylbenzene (30 mg; 15 1-1mol). The
`side chain protection was chosen as follows: Tyr(tert(cid:173)
`butyl), Glu(tert-butyl), His(trityl), Gln(trityl), Asn(trityl),
`Thr(tert-butyl),
`and Lys(tert-butyloxy-carbonyl), Ser(cid:173)
`(trityl). Double coupling procedures were performed with
`diisopropylcarbodiimide /1-hydroxy-benzotriazole activa(cid:173)
`tion, sevenfold excess and a coupling time of 40 min.
`The linear peptide amides were cleaved with trifiuoro(cid:173)
`acetic acid/thioanisole/thiocresol within 3 h and precipi(cid:173)
`tated from cold diethyl ether. The products were collected
`by centrifugation and resuspended twice in diethyl ether.
`Finally they were lyophilised from water/tert-butyl alcohol
`(1:2).
`The peptides were purified to homogeneity higher than
`94% by reversed-phase HPLC on a nucleosil C-18 column,
`6 j.Lm, 25 X 300 mm (Waters), using acetonitrile/water
`mixed with 0.1% trifiuoroacetic. acid as eluent. !socratic
`conditions between 20-30% acetonitrile were applied,
`depending on the polarity of the peptide. Analysis of the
`peptides was performed on a nucleosil C-18 column, 5
`j.Lm, 3 X 125 mm (Merck-Hitachi) by a gradient of 15-
`60% acetonitrile over 30 min.
`Correct mass was identified by ion-spray mass spec(cid:173)
`trometry (API III, Sciex, Toronto).
`
`2.2. Circular dichroism
`
`Circular dichroism spectra were measured over 250-190
`nm on a Jasco 1720 spectrapolarimeter at room tempera-
`
`ture in nitrogen atmosphere. The peptides were dissolved
`in 2,2,2-trifiuoroethanol/phosphate buffer (pH= 7, 10
`mM) in the ratio 317, at concentrations of 0.20-0.22 mM.
`All measurements were performed three times using a
`sample cell with path length of 0.2 mm. Response time
`was set to 2 s at a scan speed of 20 nm/min, a sensitivity
`range of 10 mdeg, a band width of 2.0 nm and a step
`resolution of 0.1 nm. High-frequency noise was reduced by
`means of a low-path Fourier-transform filter. The circular
`dichroism spectra of pure solvents were subtracted from
`the peptide solution to eliminate interference from cell,
`solvent and optical equipment. The circular dichroism data
`are given as mean residue ellipticities [ e] m.
`
`2.3. Membrane preparation
`
`SK-N-MC cells were cultivated in Dulbecco's modified
`Eagle medium. The medium of confluent culture was
`removed and the cells· were washed twice with PBS-buffer.
`The cells were detached by the addition PBS-buffer,
`supplemented with 0.02% EDTA. Resuspended in 20 ml
`Balanced Salts Solution (BSS (in mM): NaCI 120, KCl
`5.4, NaHC0 3 16.2, MgS0 4 0.8, NaH2 P0 4 1.0, CaC1 2 1.8,
`o-glucose 5.5, HEPES 30, pH 7.40) the cells were cen(cid:173)
`trifuged twice at 100 X g and resuspended in BSS. After
`determination of their number, the cells are homogenised
`using an Ultra-Turrax and centrifuged for 10 min at
`3000 X g (4°C). The supernatant was discarded and the
`pellet was resuspended in Tris buffer (10 mM Tris, 50 mM
`NaCI, 5 mM MgCl 2 , 1 mM EDTA, pH 7.40) sup(cid:173)
`plemented with 1% bovine serum albumin and 0.1%
`bacitracin, recentrifuged and resuspended (1 ml/1 000 000
`cells). The homogenate was frozen at - 80°C. The mem(cid:173)
`brane preparations are stable for more than 6 weeks.
`
`2.4. Receptor binding
`
`After thawing the homogenate was diluted 1:10 with
`assay buffer (50 mM Tris, 150 mM NaCI, 5 mM MgC1 2 , 1
`mM EDTA, pH 7.40) and treated for 30 s with an Ultra(cid:173)
`Turrax. Then, 230 1-11 of the homogenate were incubated
`for 180 min at
`room
`temperature with 50 pM
`125I]iodotyrosyl-calcitonin gene-related peptide and in(cid:173)
`[
`creasing concentrations of the test compound in a total
`volume of 250 1-11. The incubation is terminated by either
`centrifugation for 10 min at 2900 X g or filq-ation through
`polyethylene imine (0.1% )-treated GF /B glass fibre filters
`using a cell harvester. The protein-bound radioactivity is
`determined in a gamma-counter. The non-specific binding
`is defined as radioactivity bound in the presence of 1 1-1M
`human CGRP1 during the incubation period. Half maximal
`inhibition of the specific binding of [125l]iodohistidyl(cid:173)
`calcitonin gene-related peptide of three separate experi(cid:173)
`ments each performed in triplicate is given as the K1 value
`(Table 1) ±S.E.M. (Fig. 1). Data analysis was performed
`with GraphPad.
`
`2
`
`

`

`B. Rist et al. I Regulatory Peptides 79 (1999) 153-158
`
`155
`
`2.5. Blood flow
`
`Experiments were carried out in adult female Wistar rats
`weighing between 250 and 280 g anaesthetized with
`sodium pentobarbitone (Nembutal, Boehringer-Ingelheim;
`60 mg/kg, intraperitoneal). Intravenous supplements of
`pentobarbitone were given to maintain anaesthesia. The
`trachea was cannulated and connected to a positive pres(cid:173)
`sure rodent ventilator (Ugo Basile 6025). The left femoral
`artery was cannulated for continuous recording of arterial
`blood pressure via a Gould-Statham physiological pres(cid:173)
`sure transducer (P23XL) which was connected to one
`channel of a pen recorder (Graphtec WR7500). Tempera(cid:173)
`ture was continuously monitored via a rectal probe (Di(cid:173)
`gitron Model 1808) and kept in the range 36± 1 °C. The
`electrocardiogram was
`recorded
`through subcutaneous
`needle electrodes and displayed on a storage oscilloscope.
`The electrocardiogram was used to obtain beat-by-beat
`pulse interval (PI) after processing with Neurolog modules
`(Digitimer, UK, NL200,304,600). Triggering was checked
`with a counter. PI was preferred to heart rate because of
`the linear relation between PI and frequency of vagal
`stimulation. Both vagus nerves were cut high in the neck.
`This was done to eliminate vagally-mediated reflex effects
`on the heart which occur when blood pressure is decreased
`by CGRP. The left femoral vein was cannulated for
`administration of CGRP and analogues of CGRP, as well
`as further doses of anaesthetic. The right femoral artery
`was exposed and separated from the right femoral vein and
`saphenous nerve, and the perivascular portion of the flow
`probe was placed around the femoral artery. Blood flow
`was measured in the right femoral artery using a perivascu(cid:173)
`lar flow probe (Model 0.5VB 152 Transonic systems). The
`cavity created for the probe was filled with K-Y lubricating
`jelly (Johnson & Johnson) to provide acoustic coupling to
`the probe. The flowprobe was connected to an ultrasonic
`volume flowmeter (Model T106 Transonic Systems) which
`in turn was connected to a polygraph (Grass Model 79) for
`data analysis.
`Doses of CGRP (0.5 nmol!kg) were administered
`intravenously to obtain a control response. This dose was
`selected because it decreased the resting blood pressure by
`an average 40 mmHg. When controls were obtained a
`bolus injection of the CGRP analogue, 0.17 ~J.mol/kg or
`0.068 f.LmOl!kg was administered followed by a dose of
`CGRP within 10 min. Additional doses were given if the
`response to CGRP was attenuated. Experiments were
`performed in quadruplicate and data are shown±S.E.M.
`(Fig. 3). Data were analyzed using Student's t-test and
`P < 0.05 was found for significant values.
`
`2.6. Materials
`
`Fmoc-protected amino acids were obtained from Alexis
`(Uiufelfingen, Switzerland), 4-(2' ,4'-dimethoxyphenyl(cid:173)
`Fmoc-aminomethyl)-phenoxy resin from NovaBiochem
`
`(Uiufelfingen, Switzerland), diisopropylcarbodiilnide and
`thiocresol from Aldrich, 1-hydroxybenzotriazole, diiso(cid:173)
`propylethylamine, 2,2,2-trifl.uoroethanol,
`trifl.uoroacetic
`acid, thioanisole and piperidine from Fluka and dimethyl(cid:173)
`formamide (p.a. grade), diethyl ether, acetonitrile and tert(cid:173)
`butyl alcohol from Merck. HEPES, Tris, bovine serum
`albumin, bacitracin were purchased from Sigma, poly(cid:173)
`ethylenimine from Serva, Dulbecco's modified Eagle
`medium and PBS-buffer (041-04190 M) from Gibco.
`EDT A and all salts for buffer preparation were either from
`
`Fluka or from Merck. e25I]Iodohistidyl-calcitonin gene
`
`related peptide was ordered from Amersham.
`
`3. Results
`
`3.1. Receptor binding studies
`
`The peptides that are listed in Table 1 have been
`obtained by multiple automatic solid phase peptide syn(cid:173)
`thesis. They have been characterised by analytical HPLC
`and electrospray mass spectrometry. CGRP1 receptor af(cid:173)
`finity was investigated at human neuroblastoma cells SK(cid:173)
`N-MC (Fig. 1). The most potent peptidic compounds are
`derived from CGRP 27-37 and [D 31 ]CGRP 27-37 which
`themselves only have a minor potency (Ki 728 and 2390
`nM, respectively). The introduction of a proline in position
`34 (no. 2, 5) leads in both segments to a 6- to 10-fold
`increased affinity. Within these modified segments, the
`replacement of Glu in position 35 by Phe (no. 3, 6)
`furthermore improves binding by one order of magnitude,
`thus leading to analogues with Ki values of 19 and 14 nM.
`
`3.2. Circular dichroism investigations
`
`In Fig. 2a the circular dichroism spectra of the ligands
`with low affinity (no. 1, 4) are compared with those in
`which proline in position 34 was introduced (no. 2, 5). The
`secondary structure in solution does not seem to be
`signi:ficantly affected by the exchange of S 34 to P 34
`,
`because the circular dichroism spectra of CGRP 27-37 and
`[D 3 1]CORP 27-37 are very similar to
`the ones of
`[P3'lCGRP 27-37 and [D 3
`\ P 34]CGRP 27-37, respective-
`
`Table I
`Sequences of CORP 27-37 analogs and their affinity to the CORP,
`receptor, investigated on human neuroblastoma SK-N-MC cells
`
`No.
`
`Peptide
`
`Sequence
`
`hCORP,
`K; (nM)
`
`CGRP 27-37
`[P34]CGRP 27-37
`[P 34
`, F" ]CGRP 27-37
`[D"]CGRP 27-37
`, P34]CGRP 27- 37
`[D 31
`[D", P34
`, F"]CGRP 27-37
`
`FVPTNVGSEAF
`FVPTNVGPEAF
`FVPTNVGPFAF
`FVPTDVGSEAF
`FVPTDVGPEAF
`FVPTDVGPFAF
`
`728
`123
`19
`2390
`226
`14
`
`2
`3
`4
`5
`6
`
`3
`
`

`

`156
`
`B. Rist et al. I Regulatory Peptides 79 (1999) 153-158
`
`a
`
`120
`
`'0
`§ 100
`.8
`ll. 80
`a:
`~
`0
`N ...
`ID-
`"ifl.
`
`0
`-11
`
`-10
`
`b
`
`120
`
`'0
`§ 100
`.8 eo
`ll. a:
`~
`0
`N ...
`ID-
`40
`"ifl. 20
`
`60
`
`-6
`-5
`-7
`-8
`-9
`Competitor log [M]
`
`-4
`
`-3
`
`0
`-12
`
`-11
`
`.g
`-6
`-10
`-7
`-8
`Competitor log [M]
`
`-5
`
`-4
`
`Fig. 1. Inhibition of specific [ 125I]CGRP binding to SK-N-MC cell
`membranes by peptide no. I <•), no. 2 (_.), no. 3 (T) (a) and by peptide
`no. 4 (+), no. 5 (0) and no. 6 (D) (b) as described in Section 2. Data
`represent tbe mean±S.E.M. of three determinations.
`
`---- FVPTDVGSEAF
`-----· ~GSEAF
`FVPTDVGPEAF
`- FVPTNVGPEAF
`
`-
`
`-
`
`Wavelength[ run]
`
`250
`
`---- FVPTDVGPFAF
`----- · FVPTNVGPF AF
`-
`FVPTDVGPEAF
`- - - ~GPEAF
`
`15000
`
`a
`
`Mol. Ellip.
`
`-15000
`190
`
`15000
`
`b
`
`Mol. Ellip.
`
`-15000L------1----~----....1...----~--___JL..._ __ ---l
`250
`190
`Wavelengtb[nm)
`
`Fig. 2. Comparative circular dich~oism spectra of the CGRP 27-37
`analogs.
`
`·ly. Therefore we conclude that the proline in position 34
`does not induce an unusual three dimensional arrangement,
`moreover it serves to stabilise a tum which is already
`present in the unmodified segment.
`Fig. 2b shows the effect on secondary structure of the
`[P 34
`] peptides, when Glu in position 35 is replaced by Phe,
`additionally. In this case, a significant effect on the
`secondary structure could be observed, which is indicated
`by a change-of the symmetry of the obtained curves. The
`characteristic wavelength at which the molar ellipticity of
`zero is detected, has shifted to a higher wavelength in the
`[P 34
`, F 35
`] peptides compared to [P 34
`] analogues. Further- ·
`more, a shift of the maximum and minimum of the circular
`dichroism spectra has been detected. The intensity of the
`positive Cotton effect in the range of 192-196 nm is
`, F35
`[P34
`[D 3
`p 34
`increased considerably.
`and
`]-
`,
`\
`F 35]CGRP 27-37 exhibit the most ordered structures
`within the whole set of peptides. The increase in binding
`affinity which is gained by the introduction of Phe in
`
`position 35 correlates with a particular change in sec(cid:173)
`ondary structure.
`
`3.3. Blood flow measurements
`
`In order to investigate the functional role of the CGRP
`segments, the changes in vascular conductance in the
`femoral artery (Vcfa) of rat have been measured. A dose of
`CGRP which decreased the resting blood pressure by 40
`mmHg was applied. CGRP led to an increase in Vcfa of 85
`to 90% compared to control animals without CGRP
`administration (Fig. 3a and b, grey bars). The effect of
`CGRP is reduced to less than 20% increase in Vcfa after 8
`min. For testing the CGRP analogues, the peptides were
`pre-injected to the application of CGRP. The increase of
`Vcfa was significantly reduced compared to the effect of
`CGRP without pre-injection of the peptides (65% in the
`case of 170 nmollkg [D 3
`\ P 34
`, F 35]CGRP 27-37, 58% in
`
`4
`
`

`

`B. Rist et al. I Regulatory Peptides 79 (1999) 153-158
`
`157
`
`100
`
`1 a
`
`80
`
`FVPTDVGPFAF
`
`•CGRP
`• analog+ CGRP
`D 30 min+ CGRP
`
`~60
`
`~-.. .. ..
`
`~ 40
`.5
`~
`> 20
`
`Omin
`
`1 min
`
`2 min
`
`4 min
`
`8 min
`
`FVPTNVGPFAF
`
`DCGRP
`• analog + CGRP
`030 min+ CGRP
`D 60 min + CGRP
`
`0
`
`-20
`
`b
`
`100
`
`80
`
`~ 60 c .. ..
`"' ~ 40
`.5
`.!!!
`0
`> 20
`
`0
`
`Omin
`
`1 min
`
`2 min
`
`4min
`
`8 min
`
`Fig. 3. Effects of i.v. injection of endogenous CORP (0.5 nmol/kg) on
`the vascular conductance in the femoral artery (Vcfa) of the rat in vivo
`, F 35]CGRP 27-37
`before and after i.v. pretreatment with (a) [D", P34
`(170 nmollkg) and (b) [P 34
`, F 35]CGRP 27-37 (170 nmol/kg).
`
`, F 35]CGRP 27-37, com(cid:173)
`the case of 170 nmollkg [P 34
`pared to 90% and 85%, respectively). At a dose of 68
`nmollkg the effect was less pronounced but still signifi(cid:173)
`cant. Even after 8 min, there was still a difference between
`the pre-injection of CGRP segments and without peptides
`(Fig. 3, dark bars). After 30 min CGRP was injected again.
`, F35JCGRP 27-37 no significant
`In the case of [D 31
`, P34
`difference neither in immediate Vcfa increase nor after 8
`min was found compared to the application of CGRP
`without pre-injection of the CGRP segment (Fig. 3a, white
`bars). However, in the case of [P 34
`, F 35]CGRP 27-37, the
`blocking effect of the CGRP segment was further in(cid:173)
`creased after 30 min to an increase of Vcfa to only 33%
`(Fig. 3b white bars) (compared to 85% ). Only a third
`application of CGRP after 60 min showed the same Vcfa
`increase as before the injections of the CGRP segment
`(Fig. 3b light grey bars). Injection of the CGRP segments
`
`, F35]CGRP 27-37 and [P34
`, P34
`[D 31
`showed no change in Vcfa per se.
`
`, F 35]CGRP 27-37
`
`4. Discussion and conclusion
`
`,
`
`[P 34
`analogues
`corresponding
`the
`Comparing
`,
`F 35]CGRP 27-37 and [D 31
`, P 34
`, F 35]CGRP 27-37, which
`only differ in position 31, it became evident that Asp 31
`instead of Asn 31 has no significant effect on both receptor
`recognition and secondary structure. In contrast, however,
`significant differences were found in the rat blood pressure
`in vivo assays. Both analogues show no agonistic effect
`per se, but inhibit the effect of exogenous CGRP. Thus,
`both peptides act as antagonists. However, although the
`two peptides do not distinguish in their primarily antago(cid:173)
`nistic effect at the tested concentrations (estimated pA2
`values were 6.60 and 6.64, respectively), they show
`significant differences in their half life.
`p 34
`[D 3
`Whereas
`the
`inhlbition of CGRP by
`\
`F 35]CGRP 27-37
`[P 34
`lasts
`for maximal 30 min,
`,
`35 F ]CGRP 27-37 shows a strong effect up to an hour.
`Further investigations revealed that the extent as well as
`the duration of the effect which is caused by [D 3
`\ P 34
`,
`F 35]CGRP 27~37 is very similar to that of the known
`[P 34
`antagonist CGRP 8-37
`[13-15], whereas
`for
`,
`F 35]CGRP 27-37 the duration is at least twofold in(cid:173)
`creased.
`Differences in the noncompetitive, irreversible receptor
`binding of the two analogues could be speculated, however
`no differences in the background of the binding assays
`were found.
`Since both ligands exhibit receptor binding affinities in
`the same range (Ki = 19114 nM), we suggested that the
`analogue with Asp 31 is faster metabolised, perhaps because
`of an increased susceptibility for proteases. This effect
`could be confirmed by preliminary results with other
`analogues (no. 2, 5) containing either Asp or Asn in
`position 31. In this case as well, the effect of the Asp(cid:173)
`containing peptides was significantly increased.
`Thus we conclude that circular dichroism measurements
`allow discrimination between the analogues which exhibit
`high receptor affinity (no. 3, 6) and those with low binding
`affinity (no. 1, 4). We could how that binding of the
`analogues CGRP 27-37 and [D 3 1]CGRP 27-37 is very
`sensitive to changes in position 34 35. A p 31 instead of
`Asn 31 does not effect affinity, but has major effect upon
`the half life of the analogues in vivo. Asn 31 seems to be
`necessary to prevent rapid degradation of [P34
`, F 35]CGRP
`27-37 and may therefore result in longer lasting antago(cid:173)
`nistic effects.
`
`Acknowledgements
`
`The present study was supported by grants from the
`
`5
`
`

`

`158
`
`B. Rist eta/. I Regulatory Peptides 79 (1999) 153-158
`
`Swiss National Fund for Scientific Research No. 32-
`37872.93. We thank Margaret Smith-White for expert
`technical assistance.
`
`References
`
`[1] Amara SG, Jonas V, Rosenfeld MG, Ong ES, Eavens RM. Alter(cid:173)
`native RNA processing in calcitonin gene expression generates
`rnRNAs
`encoding different polypeptides products. Nature
`1982;298:240-4.
`[2] Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko
`PE, Rivier J, Vale WW, Evans RM. Production of a novel neuro(cid:173)
`peptide encoded by the calcitonin gene via tissue-specific RNA
`processing. Nature 1983;304: 129-35.
`[3] Amara SG, Arriza JL, Swanson LW, Eavens RM, Rosenfeld MG.
`Expression in brain of a messenger RNA encoding a novel neuro(cid:173)
`peptide homologous to calcitonin gene related peptide. Science
`1985;229: 1094-7.
`[4] Steenbergh PH, Hoppener JWM, Zandberg J, Van de Ven WJM,
`Jansz HS, Lips CJM. A second calcitonin/CGRP gene. FEBS Lett
`1985;183:403-7.
`[5] Van Rossum D, Hanisch UK, Quinon R. Neuroanatornical localiza(cid:173)
`tion, pharmacological characterization and functions of CGRP,
`related peptides and their receptors. Neurosci Biobehav. Rev.
`1997;21 :649-78.
`[6] Quirion R, Van Rossum D, Dumont Y, St-Pierre S, Fournier A.
`Characterization of CGRP, and CQRP2 receptor subtypes. Ann NY
`Acad Sci 1992;657:88-105.
`
`[7] Tomlinson AE, Poyner DR. Multiple receptors for calcitonin gene(cid:173)
`related peptide and amy lin on guinea-pig ileum and vas deferens. Br
`J Pharmacol 1996;117:1362-8.
`[8] Kapas S, Clark AJL. Identification of the orphan receptor gene as a
`Type 1 calcitonin gene related peptide receptor. Biochem Biophys
`Res Commun 1995;217:832-8.
`[9] Maton PN, Pradhan T, Zhou ZC, Gardner ID, Jensen RT. Activities
`of calcitonin gene-related peptide (CGRP) and related peptides at
`the CGRP receptor. Peptides 1990;11:485-9.
`[10] Chakder S, Rattan S. [TyrO]-Calcitonin gene-related peptide 28-37
`(rat) as a putative antagonist of calcitonin gene-related peptide
`response on oposum internal anal sphincter smooth muscle. J
`Pharmacol Exp Ther 1990;253:200-6.
`[11] Howitt SG, Poyner DR. The selectivity and structural determinants
`of peptide antagonists at the CGRP receptor of rat, L6 myocytes. Br
`J Pharmacol 1997;121:1000-4.
`[12] Rist B, Entzeroth M, Beck-Sickinger AG. From rnicromolar to
`nanomolar affinity: a systematic approach to identify the binding site
`of CGRP at the hCGRPl-receptor. J Med Chern 1998;41:117-23.
`[13] Donoso MV, Fournier A, StPierre S, Huidobro-Toro JP. Pharmaco(cid:173)
`logical characterization of CGRP1 receptor subtype in the vascular
`system of the rat: studies with hCGRP fragments and analogs.
`Peptides 1990;11:885-9.
`[14] Maggi CA, Chiba T, Giuliani S. Human a-calcitonin gene-related
`peptide (8-37) as an antagonist of exogenous and endo.genous
`calcitonin gene-related peptide. Eur J Pharmacol 1991 ;192:85-8.
`(15] Mimeault M, Fournier A, Dumont Y, St Pierre S, Quirion R.
`Comparative affinities and antagonistic potencies of various human
`CGRP fragments on CGRP receptors in brain and periphery. J
`Pharmaco1 Exp Ther 1991;258:1084-90.
`
`6
`
`

`

`© 1999 Elsevier Science B.V. All rights reserved.
`This journal and the individual contributions contained in it are protected under copyright by Elsevier Science B:V., and the following terms
`and conditions apply to their use:
`
`Photocopying
`Single photocopies of single articles may be made for pers~nal use as allowed by national copyright laws. Permission of the publisher and
`payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional
`purposes, resale, and all forms of document delivery. Special rates are available for ·educational institutions that wish to make photocopies
`for non-profit educational classroom use.
`
`Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone:
`( +44) 1865 843830, fax: ( +44) 1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Rights & Permissions directly
`through Elsevier's home page (http://www.elsevier.nl), selecting first 'Customer Support', then 'General Information', then 'Permissions
`Query Form'.
`
`In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers,
`MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance
`Service (CLARCS), 90 Tottenham Court Road, London W1P OLP, UK; phone: (+44) 171 436 5931; fax: (+44) 171 436 3986. Other
`countries may have a local reprographic rights agency for payments.
`
`Derivative Works
`Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions.
`Permission of the publisher is required for resale or distribution outside the institution.
`
`Permission of the publisher is required for all other derivative works, including compilations and translations.
`
`Electronic Storage or Usage
`Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an
`article. Contact the publisher at the address indicated.
`
`Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any
`means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.
`
`Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above.
`
`Notice
`No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability,
`negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.
`Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
`
`Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a
`guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
`
`7
`
`

`

`i L v i
`
`MmmUmR
`
`V ’
`
`i
`
`9
`
`F
`
`9
`
`.
`
`,
`
`“an“. .-
`i...‘_rn'.l
`'H scum? '
`University of \ ·•
`University of
`:_
`
`MAR 2 3 ·;:>:1
`
`8
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket